Investor Relations

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

November Corporate Presentation

Stock Info
NASDAQVIRX
Recent News
Nov 29, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted its...

Nov 10, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the third quarter of 2021 and provided an...

Nov 5, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced that the Company has entered into a loan and...

View All

Events
Monday, November 29, 2021 - Thursday, December 2, 2021

Conference Dates: November 29 – December 2, 2021
Presentation Available: November 22, 2021, at 10:00 AM ET

Monday, November 29, 2021 - Thursday, December 2, 2021

Presentation Date: December 2, 2021
Presentation Time: 3:55 PM ET

Tuesday, November 16, 2021 - Wednesday, November 17, 2021
5:40am EST

Presentation Date: November 17, 2021
Presentation Time: 10:40 AM GMT/ 5:40 AM ET

View All

Investor Contact

Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com